Labviva, a Boston, MA-based AI-driven procurement platform for life sciences, has raised $25 million in a Series B funding round. 

Investors 

The round was led by 53 Stations, with participation from Biospring Partners, B Capital Group, and Glasswing Ventures. This latest investment brings Labviva’s total funding to $55 million. 

53 Stations is a Chicago-based early-stage VC firm investing in the built world, wealth tech, restaurant tech, and digital health. 53 Stations invests in seed to Series B stage companies, both leading and co-investing, and offers access to mature businesses in TPO’s portfolio for strategic guidance and potential partnerships. 

Jason Pritzker, Co-Founder of 53 Stations, joins the company’s Board of Directors. 

Labviva Use of Funds 

The new funds will support product development, international expansion, and enhanced marketing and customer support. 

About Labviva 

Labviva provides AI-driven procurement platform designed for the life sciences industry. It connects suppliers, purchasing departments, and scientists, offering tools to automate and optimize laboratory procurement processes. Labviva empowers life sciences organizations to reduce research costs, avoid inventory gaps, and focus resources on innovation. Its mission is to unify the life sciences supply chain. 

Funding Details 

Company: Labviva, Inc. 

Raised: $25.0M 

Round: Series B 

Funding Month: January 2025 

Lead Investor: 53 Stations 

Additional Investors: Biospring Partners, B Capital Group, Glasswing Ventures 

Company Website: https://www.labviva.com/  

Software Category: AI Procurement 

Source: Gabby Lescarbeau